Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Related Citations for PubMed (Select 20696881)

1.

Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.

Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M.

Antimicrob Agents Chemother. 2010 Oct;54(10):4059-63. doi: 10.1128/AAC.00747-10. Epub 2010 Aug 9.

2.

Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.

Mugabo P, Els I, Smith J, Rabie H, Smith P, Mirochnick M, Steyn W, Hall D, Madsen R, Cotton MF.

S Afr Med J. 2011 Sep 5;101(9):655-8.

PMID:
21920159
3.

Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.

Abel S, Davis JD, Ridgway CE, Hamlin JC, Vourvahis M.

Antivir Ther. 2009;14(6):831-7. doi: 10.3851/1297.

PMID:
19812445
4.

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.

Rosario MC, Jacqmin P, Dorr P, James I, Jenkins TM, Abel S, van der Ryst E.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:86-94. doi: 10.1111/j.1365-2125.2008.03140.x.

5.

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.

Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A.

J Antimicrob Chemother. 2012 Jan;67(1):206-12. doi: 10.1093/jac/dkr427. Epub 2011 Oct 10.

6.

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.

Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:54-9. doi: 10.1111/j.1365-2125.2008.03136.x.

7.

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.

Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, Moore JP.

J Antimicrob Chemother. 2013 Mar;68(3):678-83. doi: 10.1093/jac/dks422. Epub 2012 Oct 30.

8.

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.

Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, Kashuba AD.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53. doi: 10.1097/QAI.0b013e3181ae69c5.

9.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
10.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
11.

Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.

Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP.

Antimicrob Agents Chemother. 2012 May;56(5):2251-8. doi: 10.1128/AAC.05810-11. Epub 2012 Feb 13.

12.

A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.

Rosario MC, Jacqmin P, Dorr P, van der Ryst E, Hitchcock C.

Clin Pharmacol Ther. 2005 Nov;78(5):508-19. Epub 2005 Sep 28.

PMID:
16321617
13.

Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations.

Takahashi M, Hirano A, Okubo N, Kinoshita E, Nomura T, Kaneda T.

J Med Invest. 2010 Aug;57(3-4):245-50.

14.

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:47-53. doi: 10.1111/j.1365-2125.2008.03135.x.

15.

Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.

Vourvahis M, Fang J, Checchio T, Milton A, Weatherley B, McFadyen L, Heera J.

HIV Clin Trials. 2013 May-Jun;14(3):99-109. doi: 10.1310/hct1403-99.

PMID:
23835512
16.

Maraviroc: pharmacokinetics and drug interactions.

Abel S, Back DJ, Vourvahis M.

Antivir Ther. 2009;14(5):607-18. Review.

PMID:
19704163
17.

Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Massud I, Aung W, Martin A, Bachman S, Mitchell J, Aubert R, Solomon Tsegaye T, Kersh E, Pau CP, Heneine W, GarcĂ­a-Lerma JG.

J Virol. 2013 Aug;87(16):8952-61. doi: 10.1128/JVI.01204-13. Epub 2013 Jun 5.

18.
19.

Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.

Ramanathan S, Abel S, Tweedy S, West S, Hui J, Kearney BP.

J Acquir Immune Defic Syndr. 2010 Feb;53(2):209-14. doi: 10.1097/QAI.0b013e3181ba4536.

PMID:
19851115
20.

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB.

AIDS. 1999 Mar 11;13(4):479-86.

PMID:
10197376
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk